M20 Genomics Expands European Research Collaboration with VITA Platform at University Hospital Heidelberg

Singapore, January 2025 – M20 Genomics is proud to announce the successful installation of its cutting-edge VITA Single-Cell Full-Length Transcriptome Platform at the prestigious University Hospital Heidelberg. This milestone marks a new chapter in our European research collaboration, bringing our advanced, high-throughput single-cell sequencing products and technical support to one of the world’s leading academic and medical institutions.

Photograph of both teams

Empowering Research with Cutting-Edge Single-Cell Technology

Following the installation of the VITA platform, M20 Genomics’ technical team conducted comprehensive training for researchers at University Hospital Heidelberg. The sessions covered critical aspects, including experimental workflows, reagent application, and data analysis, ensuring the platform operates at its full potential.

The VITA platform at University Hospital Heidelberg will now serve as a central hub for collaborative research in Europe, providing single-cell sequencing services to the hospital and neighboring institutions. Plans are already underway to extend these services to additional clients across the continent.

By integrating the VITA platform, University Hospital Heidelberg aims to advance its research on eukaryotic and gut microbiome samples. The laboratory anticipates that this cutting-edge technology will not only strengthen its single-cell sequencing capabilities but also drive significant breakthroughs in medical research and clinical applications, contributing to scientific progress both in Europe and globally.

M20 Genomics is thrilled to embark on this partnership and looks forward to pushing the boundaries of single-cell sequencing research alongside University Hospital Heidelberg.

VITA Platform Training Session at University Hospital Heidelberg

About University Hospital Heidelberg

Located in the heart of Heidelberg, Germany, University Hospital Heidelberg (Universitätsklinikum Heidelberg) is one of Europe’s largest and most renowned medical centers. As a key institution for advanced medical research, it is integrated with Heidelberg University Medical School, which is consistently ranked among the world’s top medical schools. The hospital specializes in a wide range of research areas, including oncology, immunology, neurology, and infectious diseases. With state-of-the-art facilities and a commitment to both clinical excellence and groundbreaking scientific discovery, University Hospital Heidelberg serves as a hub for innovation, offering unparalleled opportunities for cross-disciplinary collaborations with global research institutions.

About M20 Genomics

M20 Genomics is a rapidly growing life science technology company dedicated to pushing the boundaries of single-cell and spatial technologies. Our mission is to empower our customers by overcoming technological barriers in cutting-edge single-cell and spatial technologies, unraveling mysteries in life science, and driving advancements in disease diagnosis and treatment. With M20 Seq technology, we have pioneered the world's first high-throughput full-length single-cell technology sequencing using random primers, along with our VITA product line for single-cell transcriptome sequencing. VITA represents the world’s first commercially available platform also applicable to microbiological samples. In addition, our M20 Spatial technology, utilizing random primers and paired with our NATA spatial transcriptome product line, provides the first spatial full-transcriptome solution across various sample types. To learn more about our transformative technologies, visit the M20 Genomics website or follow us on LinkedIn or X.